Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
IMM
London, United Kingdom
- Ownership
- Private
- Employees
- ~6
- Development stage
- Other
01
Overview
Lead asset P140 (Lupuzor™) has completed a Phase 3 trial in systemic lupus erythematosus (superior response over placebo, but did not reach statistical significance); re-enrollment with optimized protocol is planned. P140 for CIDP is in a pivotal Phase 2/3. Anti-infective assets are preclinical. Partnership with Avion Pharmaceuticals for US commercialization; additional licensing ongoing.
- Therapeutic areas
- ImmunologyRheumatologyInfectious DiseasesGastroenterologyPulmonologyNeurology
- Modalities
- PeptidesSmall molecule
- Industry
- Biotech
02
Partnerships
Avion Pharmaceuticals (exclusive US license/development)Centre National de la Recherche Scientifique (France)
Beyond the preview
Go deeper on IMM.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMM.